These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 220536)

  • 1. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections.
    Cheeseman SH; Rubin RH; Stewart JA; Tolkoff-Rubin NE; Cosimi AB; Cantell K; Gilbert J; Winkle S; Herrin JT; Black PH; Russell PS; Hirsch MS
    N Engl J Med; 1979 Jun; 300(24):1345-9. PubMed ID: 220536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts.
    Balfour HH; Chace BA; Stapleton JT; Simmons RL; Fryd DS
    N Engl J Med; 1989 May; 320(21):1381-7. PubMed ID: 2541335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients.
    Hirsch MS; Schooley RT; Cosimi AB; Russell PS; Delmonico FL; Tolkoff-Rubin NE; Herrin JT; Cantell K; Farrell ML; Rota TR; Rubin RH
    N Engl J Med; 1983 Jun; 308(25):1489-93. PubMed ID: 6304513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
    J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.
    Soulillou JP; Cantarovich D; Le Mauff B; Giral M; Robillard N; Hourmant M; Hirn M; Jacques Y
    N Engl J Med; 1990 Apr; 322(17):1175-82. PubMed ID: 2157982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
    N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus infection in renal transplant recipients. Effects of antithymocyte globulin and interferon.
    Cheeseman SH; Henle W; Rubin RH; Tolkoff-Rubin NE; Cosimi B; Cantell K; Winkle S; Herrin JT; Black PH; Russell PS; Hirsch MS
    Ann Intern Med; 1980 Jul; 93(1):39-42. PubMed ID: 6156614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acyclovir prophylaxis of herpes-simplex-virus infections.
    Saral R; Burns WH; Laskin OL; Santos GW; Lietman PS
    N Engl J Med; 1981 Jul; 305(2):63-7. PubMed ID: 6264292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root.
    Pazin GJ; Armstrong JA; Lam MT; Tarr GC; Jannetta PJ; Ho M
    N Engl J Med; 1979 Aug; 301(5):225-30. PubMed ID: 221812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation.
    Macdonald PS; Keogh AM; Marshman D; Richens D; Harvison A; Kaan AM; Spratt PM
    J Heart Lung Transplant; 1995; 14(1 Pt 1):32-8. PubMed ID: 7727473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients.
    Snydman DR; Werner BG; Heinze-Lacey B; Berardi VP; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS
    N Engl J Med; 1987 Oct; 317(17):1049-54. PubMed ID: 2821397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
    Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
    Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.
    Valenza M; Czer LS; Pan SH; Aleksic I; Freimark D; Harasty DA; Admon D; Barath P; Blanche C; Trento A
    J Heart Lung Transplant; 1995; 14(4):659-65. PubMed ID: 7578172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials.
    Tian JH; Wang X; Yang KH; Liu AP; Luo XF; Zhang J
    Transplant Proc; 2009 Nov; 41(9):3671-6. PubMed ID: 19917365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.
    Merigan TC; Renlund DG; Keay S; Bristow MR; Starnes V; O'Connell JB; Resta S; Dunn D; Gamberg P; Ratkovec RM
    N Engl J Med; 1992 Apr; 326(18):1182-6. PubMed ID: 1313549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon for prevention of cytomegalovirus reactivation in renal-transplant recipients.
    Himmelstein DU; Woolhandler S
    N Engl J Med; 1983 Nov; 309(19):1193. PubMed ID: 6194436
    [No Abstract]   [Full Text] [Related]  

  • 18. Polyvalent immune globulin and cytomegalovirus infection after renal transplantation.
    Kasiske BL; Heim-Duthoy KL; Tortorice KL; Ney AL; Odland MD; Rao KV
    Arch Intern Med; 1989 Dec; 149(12):2733-6. PubMed ID: 2556978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acyclovir and renal transplantation.
    Pettersson E; Eklund B; Höckerstedt K; Salmela K; Ahonen J
    Scand J Infect Dis Suppl; 1985; 47():145-8. PubMed ID: 3912970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus vaccine in renal transplant candidates: progress report of a randomized, placebo-controlled, double-blind trial.
    Balfour HH; Sachs GW; Welo P; Gehrz RC; Simmons RL; Najarian JS
    Birth Defects Orig Artic Ser; 1984; 20(1):289-304. PubMed ID: 6329368
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.